Cyclosporine before PCI in Patients with Acute Myocardial Infarction.
暂无分享,去创建一个
N. Mewton | G. Rioufol | J. Dubois-Randé | G. Vanzetto | M. Morice | P. Barragan | P. Steg | M. Gilard | H. le Breton | G. Rangé | J. Labèque | G. Cayla | P. Motreff | N. Delarche | P. Coste | J. Clerc | Y. Cottin | M. Metge | O. Morel | D. Angoulvant | M. Claeys | D. Blanchard | G. Derumeaux | F. Prunier | C. Tron | C. Piot | T. Cung | E. Elmér | M. Hansson | M. Ovize | D. Garcia-Dorado | L. Belle | C. Bergerot | G. Grollier | P. Colin | F. de Poli | T. Unterseeh | A. Sudre | P. Staat | J. Aupetit | P. Guérin | O. Ider | O. Roth | V. Malquarti | P. Coussement | I. Boussaha | B. Jouve | M. Elbaz | C. Jossan | F. Moulin | P. Dubois | E. Bonnefoy-cudraz | T. Béard
[1] N. Mewton,et al. Rationale and design of the Cyclosporine to ImpRove Clinical oUtcome in ST-elevation myocardial infarction patients (the CIRCUS trial). , 2015, American heart journal.
[2] F. Van de Werf,et al. Evolving therapies for myocardial ischemia/reperfusion injury. , 2015, Journal of the American College of Cardiology.
[3] Sunil V. Rao,et al. Randomized trial of primary PCI with or without routine manual thrombectomy. , 2015, The New England journal of medicine.
[4] F. Van de Werf,et al. Cyclosporine A reduces microvascular obstruction and preserves left ventricular function deterioration following myocardial ischemia and reperfusion , 2015, Basic Research in Cardiology.
[5] F. Fernández‐Avilés,et al. Intracoronary injection of adenosine before reperfusion in patients with ST-segment elevation myocardial infarction: a randomized controlled clinical trial. , 2014, International journal of cardiology.
[6] G. Vanzetto,et al. Effect of coronary thrombus aspiration during primary percutaneous coronary intervention on one-year survival (from the FAST-MI 2010 registry). , 2014, The American journal of cardiology.
[7] Wade M. Lee,et al. Cardioprotective role of ischemic postconditioning in acute myocardial infarction: a systematic review and meta-analysis. , 2014, American heart journal.
[8] P. Ferdinandy,et al. Interaction of Risk Factors, Comorbidities, and Comedications with Ischemia/Reperfusion Injury and Cardioprotection by Preconditioning, Postconditioning, and Remote Conditioning , 2014, Pharmacological Reviews.
[9] N. Mewton,et al. Cyclosporine Protects the Heart during Aortic Valve Surgery , 2014, Anesthesiology.
[10] Michael V. Cohen,et al. Combined Cardioprotectant and Antithrombotic Actions of Platelet P2Y12 Receptor Antagonists in Acute Coronary Syndrome , 2014, Journal of cardiovascular pharmacology and therapeutics.
[11] S. Kolvekar,et al. The effect of cyclosporin-A on peri-operative myocardial injury in adult patients undergoing coronary artery bypass graft surgery: a randomised controlled clinical trial , 2014, Heart.
[12] A. Íñiguez,et al. Effect of Early Metoprolol on Infarct Size in ST-Segment–Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention: The Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) Trial , 2013, Circulation.
[13] L. Argaud,et al. Cyclosporine A at reperfusion fails to reduce infarct size in the in vivo rat heart , 2013, Basic Research in Cardiology.
[14] S. Ghaffari,et al. The effect of prethrombolytic cyclosporine-A injection on clinical outcome of acute anterior ST-elevation myocardial infarction. , 2013, Cardiovascular therapeutics.
[15] E. Elmér,et al. Bioequivalence and Tolerability Assessment of a Novel Intravenous Ciclosporin Lipid Emulsion Compared to Branded Ciclosporin in Cremophor® EL , 2012, Clinical Drug Investigation.
[16] Salil Sharma,et al. Intralipid, a Clinically Safe Compound, Protects the Heart Against Ischemia-Reperfusion Injury More Efficiently Than Cyclosporine-A , 2012, Anesthesiology.
[17] Jean-Claude Tardif,et al. Women and men with stable coronary artery disease have similar clinical outcomes: insights from the international prospective CLARIFY registry , 2012, European heart journal.
[18] G. Stone,et al. Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial. , 2012, JAMA.
[19] C. Messow,et al. Cyclosporin variably and inconsistently reduces infarct size in experimental models of reperfused myocardial infarction: a systematic review and meta‐analysis , 2012, British journal of pharmacology.
[20] P. Ferdinandy,et al. Postconditioning and protection from reperfusion injury: where do we stand? Position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. , 2010, Cardiovascular research.
[21] K. Eagle,et al. The Global Registry of Acute Coronary Events, 1999 to 2009–GRACE , 2010, Heart.
[22] G. Heusch,et al. Cyclosporine A at Reperfusion Reduces Infarct Size in Pigs , 2010, Cardiovascular Drugs and Therapy.
[23] Pierre Croisille,et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. , 2008, The New England journal of medicine.
[24] Daniel C. Lee,et al. Angiographic estimates of myocardium at risk during acute myocardial infarction: validation study using cardiac magnetic resonance imaging. , 2007, European heart journal.
[25] C. Bauters,et al. Left ventricular remodeling after anterior wall acute myocardial infarction in modern clinical practice (from the REmodelage VEntriculaire [REVE] study group). , 2006, The American journal of cardiology.
[26] Jeffrey Robbins,et al. Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death , 2005, Nature.
[27] Tetsuya Watanabe,et al. Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death , 2005, Nature.
[28] D. Yellon,et al. Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning? , 2002, Cardiovascular research.
[29] X. Bigard,et al. Effect of cyclosporin A and its vehicle on cardiac and skeletal muscle mitochondria: relationship to efficacy of the respiratory chain , 2001, British journal of pharmacology.
[30] A. Halestrap,et al. Mitochondrial non-specific pores remain closed during cardiac ischaemia, but open upon reperfusion. , 1995, The Biochemical journal.
[31] M. Duchen,et al. On the involvement of a cyclosporin A sensitive mitochondrial pore in myocardial reperfusion injury. , 1993, Cardiovascular research.
[32] M. Crompton,et al. A heart mitochondrial Ca2(+)-dependent pore of possible relevance to re-perfusion-induced injury. Evidence that ADP facilitates pore interconversion between the closed and open states. , 1990, The Biochemical journal.
[33] K. Mahaffey,et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation , 2012 .
[34] L. Becker. Myocardial Reperfusion Injury , 2004, Journal of Thrombosis and Thrombolysis.